BACKGROUND: The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We evaluated the risk of central nervous system (CNS) relapse in the R-CHOP in a population-based cohort of patients with DLBCL. METHODS: Patients with DLBCL diagnosed from 1 September 1999 to 14 January 2005 at the British Columbia Cancer Agency (BCCA) were identified. Patients were included if they were > or =16 years old with advanced stage or any stage with testicular involvement and were treated with CHOP (1999-2001) or R-CHOP (2001-2005) with curative intent. RESULTS: Four hundred and thirty-five patients were identified; 126 (29%) were treated with CHOP and 309 (71%) with R-CHOP. With a median follow-up of 5.7 years, there were 31 CNS relapses in total with a trend to a reduced likelihood of CNS relapse in R-CHOP-treated patients (3-year risk 9.7% versus 6.4, P = 0.085). In multivariate analysis, the use of rituximab significantly reduced the risk of CNS relapse [hazard ratio (HR) 0.45, P = 0.034]; this benefit was more striking in patients who achieved a complete response (HR 0.18, P = 0.005). CONCLUSION: The use of R-CHOP appears to reduce the overall risk of CNS relapse in patients with DLBCL particularly in patients who achieve a complete response.
BACKGROUND: The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We evaluated the risk of central nervous system (CNS) relapse in the R-CHOP in a population-based cohort of patients with DLBCL. METHODS:Patients with DLBCL diagnosed from 1 September 1999 to 14 January 2005 at the British Columbia Cancer Agency (BCCA) were identified. Patients were included if they were > or =16 years old with advanced stage or any stage with testicular involvement and were treated with CHOP (1999-2001) or R-CHOP (2001-2005) with curative intent. RESULTS: Four hundred and thirty-five patients were identified; 126 (29%) were treated with CHOP and 309 (71%) with R-CHOP. With a median follow-up of 5.7 years, there were 31 CNS relapses in total with a trend to a reduced likelihood of CNS relapse in R-CHOP-treated patients (3-year risk 9.7% versus 6.4, P = 0.085). In multivariate analysis, the use of rituximab significantly reduced the risk of CNS relapse [hazard ratio (HR) 0.45, P = 0.034]; this benefit was more striking in patients who achieved a complete response (HR 0.18, P = 0.005). CONCLUSION: The use of R-CHOP appears to reduce the overall risk of CNS relapse in patients with DLBCL particularly in patients who achieve a complete response.
Authors: Marta Bruno Ventre; Andrés J M Ferreri; Mary Gospodarowicz; Silvia Govi; Carlo Messina; David Porter; John Radford; Dae Seog Heo; Yeon Park; Giovanni Martinelli; Emma Taylor; Helen Lucraft; Angela Hong; Lydia Scarfò; Emanuele Zucca; David Christie Journal: Oncologist Date: 2014-02-24
Authors: Jacoline E Bromberg; Jeanette K Doorduijn; Gerald Illerhaus; Kristoph Jahnke; Agniezka Korfel; Lars Fischer; Kristina Fritsch; Outti Kuittinen; Samar Issa; Cees van Montfort; Martin J van den Bent Journal: Haematologica Date: 2012-11-09 Impact factor: 9.941
Authors: Wyndham H Wilson; Jacoline E C Bromberg; Maryalice Stetler-Stevenson; Seth M Steinberg; Lourdes Martin-Martin; Carmen Muñiz; Juan Manuel Sancho; Maria Dolores Caballero; Marjan A Davidis; Rik A Brooimans; Blanca Sanchez-Gonzalez; Antonio Salar; Eva González-Barca; Jose Maria Ribera; Margaret Shovlin; Armando Filie; Kieron Dunleavy; Thomas Mehrling; Michele Spina; Alberto Orfao Journal: Haematologica Date: 2014-04-11 Impact factor: 9.941
Authors: Agnieszka Korfel; Thomas Elter; Eckhard Thiel; Matthias Hänel; Robert Möhle; Roland Schroers; Marcel Reiser; Martin Dreyling; Jan Eucker; Christian Scholz; Bernd Metzner; Alexander Röth; Josef Birkmann; Uwe Schlegel; Peter Martus; Gerard Illerhaus; Lars Fischer Journal: Haematologica Date: 2012-12-14 Impact factor: 9.941
Authors: Rosa Bosch; María José Moreno; Rebeca Dieguez-Gonzalez; María Virtudes Céspedes; Alberto Gallardo; Manuel Trias; Albert Grañena; Jorge Sierra; Isolda Casanova; Ramon Mangues Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941